Modigraf (Tacrolimus)

Tacrolimus, the active ingredient in Modigraf, is a calcineurin inhibitor presented as an oral formulation for oral use. It is employed to reduce immune‑mediated rejection in organ transplant recipients and to modulate immune activity in selected autoimmune conditions.

GNH USA supplies Modigraf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Tacrolimus is used in transplantation medicine to inhibit T‑cell activation and prevent graft rejection.

- Kidney transplant: lowers the incidence of acute rejection and supports graft survival. - Liver transplant: reduces early rejection episodes and improves long‑term graft function. - Heart transplant: diminishes the risk of cellular rejection and prolongs graft longevity.

Tacrolimus may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tremor: fine shaking of hands or limbs. - Hypertension: elevated blood pressure readings. - Hyperglycemia: increased blood glucose levels. - Elevated serum creatinine: mild renal function changes.

Serious or Rare Side Effects: - Nephrotoxicity: significant decline in kidney function. - Neurotoxicity: seizures, confusion, or severe tremor. - Infections: opportunistic bacterial, viral, or fungal infections. - Malignancy: increased risk of lymphomas and skin cancers. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatotoxicity: abnormal liver enzymes or liver injury.

When prescribing or dispensing tacrolimus, several safety considerations are essential.

- Renal monitoring: regularly assess serum creatinine and glomerular filtration rate. - Blood pressure control: monitor and manage hypertension throughout therapy. - Glucose surveillance: check fasting glucose and HbA1c for hyperglycemia. - Lipid profile: evaluate cholesterol and triglycerides periodically. - Infection vigilance: screen for latent infections and advise on infection signs. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Tacrolimus interacts with many medicines that affect its metabolism or toxicity profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise tacrolimus levels dramatically. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower tacrolimus concentrations. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of nephrotoxicity. - Azole antifungals (e.g., fluconazole): elevate tacrolimus exposure. - Macrolide antibiotics (e.g., erythromycin): potentiate tacrolimus levels.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., diltiazem): may modestly increase tacrolimus. - Diuretics (e.g., furosemide): can affect renal handling. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Anticoagulants (e.g., warfarin): watch for altered INR. - Live vaccines: risk of infection due to immunosuppression.